Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Lifecore Biomedical (NASDAQ: LFCR) said it will participate at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026.
Company management, including Paul Josephs (chief executive officer) and Ryan Lake (chief financial officer), are scheduled to participate in 1-on-1 meetings during the conference.
Positive
- None.
Negative
- None.
News Market Reaction 25 Alerts
On the day this news was published, LFCR declined 2.16%, reflecting a moderate negative market reaction. Argus tracked a peak move of +8.7% during that session. Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $7M from the company's valuation, bringing the market cap to $328M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LFCR was up 1.16% while higher-affinity peers ACB, OGI, TKNO and SXTC showed declines between -4.18% and -9.09%, indicating stock-specific strength rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 11 | Investor conferences | Positive | +6.2% | Participation in Jefferies and Stephens conferences with presentations and meetings. |
| Nov 06 | Earnings update | Positive | -2.2% | Q3 2025 results with revenue growth, better EBITDA, and guidance details. |
| Oct 30 | Earnings scheduling | Neutral | +1.3% | Announcement of Q3 results date and related investor webcast details. |
| Oct 29 | New CDMO contract | Positive | +2.3% | New commercial manufacturing agreement and pre-clinical formulation deal. |
| Oct 28 | Collaboration deal | Positive | +2.5% | Collaboration with PolyPeptide for end-to-end peptide manufacturing in U.S. |
Recent news on collaborations, new manufacturing deals, and conference participation generally saw positive price reactions, while a fundamentally stronger earnings report drew a modest negative move, indicating occasional divergence on financial updates.
Over the last few months, Lifecore announced multiple strategic steps: a peptide manufacturing collaboration on Oct 28, 2025, a new commercial manufacturing partnership on Oct 29, 2025, and plans for reporting Q3 results on Nov 6, 2025. The actual Q3 earnings release showed revenue growth and improved profitability metrics but was followed by a small decline. Subsequent conference participation news on Nov 11, 2025 coincided with a stronger positive move. Today’s J.P. Morgan conference participation fits this pattern of ongoing investor outreach and business development visibility.
Regulatory & Risk Context
A Form S-3 filed on Sep 22, 2025 registers up to 20,456,637 common shares for resale by existing holders, including shares issuable upon conversion of Series A Convertible Preferred Stock. The filing also notes an adverse opinion on internal control effectiveness as of May 25, 2025 by the prior auditor.
Market Pulse Summary
This announcement highlights Lifecore’s participation in the 44th J.P. Morgan Healthcare Conference from January 12–15, 2026, continuing a pattern of active investor outreach following recent collaborations and commercial agreements. Investors may contextualize this with prior filings that include a Form S-3 for up to 20,456,637 resalable shares and disclosures of internal control weaknesses. Monitoring future updates from the conference and subsequent SEC filings will be important for assessing execution and capital structure developments.
Key Terms
contract development and manufacturing organization technical
cdmo technical
AI-generated analysis. Not financial advice.
CHASKA, Minn., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 44th Annual J.P. Morgan Healthcare Conference. The conference will take place January 12-15, 2026, in San Francisco, California.
Details regarding Lifecore’s participation are as follows:
- 44th Annual J.P. Morgan Healthcare Conference
Details: Lifecore management, including Paul Josephs, chief executive officer, and Ryan Lake, chief financial officer, will participate in 1-on-1 meetings
Conference Dates: January 12-15, 2026
Location: San Francisco, California
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
Lifecore Biomedical, Inc. Contact Information: Vida Strategic Partners Stephanie Diaz (Investors) 415-675-7401 sdiaz@vidasp.com Tim Brons (Media) 415-675-7402 tbrons@vidasp.com Ryan D. Lake (CFO) Lifecore Biomedical 952-368-6244 ryan.lake@lifecore.com
FAQ
When will Lifecore (LFCR) attend the 44th Annual J.P. Morgan Healthcare Conference?
Which Lifecore executives will attend the J.P. Morgan conference for LFCR?
What type of meetings will Lifecore (LFCR) hold at the January 2026 J.P. Morgan conference?
Is there a public presentation or webcast for Lifecore (LFCR) at the J.P. Morgan conference?
Where is the 44th Annual J.P. Morgan Healthcare Conference taking place for LFCR attendees?
How can investors request a meeting with Lifecore (LFCR) at the J.P. Morgan conference?
